Epeleuton is a synthetic prodrug of an endogenous downstream metabolite of eicosapentaenoic acid.
TRIAGE (ClinicalTrials.gov Identifier: NCT04365400) is a randomised, double-blind, placebo-controlled, dose finding Phase IIb study being conducted in Germany, Israel, Latvia, Switzerland and the United States to assess the efficacy and safety of orally administered epeleuton in 240 patients with hypertriglyceridemia and type 2 diabetes.
Patients will receive either epeleuton (2 or 4 g/day) or placebo for 26 weeks. The primary outcomes will be %age change in triglycerides from baseline to week 16 and change in HbA1c from baseline to week 26. Data are expected in Q4 2021.
Epeleuton, previously named DS102, is 15-hydroxy eicosapentaenoic acid -HEPE) ethyl ester, a second-generation synthetic n-3 fatty acid and derivative of an endogenous downstream metabolite of EPA. Epeleuton is a new chemical entity with additional therapeutic effects compared with other n-3 fatty acids.
The epeleuton Phase 2a data is published in the peer-reviewed Journal of the American Heart Association.
Afimmune is a clinical stage drug discovery and development company developing biologically active polyunsaturated lipids for the treatment of metabolic disorders, such as dyslipidemia, type 2 diabetes, non-alcoholic steatohepatitis, and cardiovascular disease.
The company is headquartered in Dublin, Ireland.
argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results
Sanofi's riliprubart receives orphan drug designation in Japan for CIDP
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Hikma Pharmaceuticals USA announces USD1bn of new US investment
UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder